跳至主要内容
临床试验/CTRI/2019/05/019342
CTRI/2019/05/019342尚未招募未知

COMPARISION OF SILODOSIN VERSUS TADALAFIL IN PATIENTS WITH LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA - STIPSS

Dr Mapranathukaran Devassy Robin0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • 1 Men aged more than 45 years with diagnosis of BPH with LUTS based on history, clinical examination with digital rectal examination and ultrasound Kidney , Ureter and Bladder(KUB) with post void residual volume
  • 2 Baseline (week 0) conditions satisfying the following
  • a Total international prostate symptom score(IPSS) more than or equal to 13
  • b IPSS quality of life (QoL) Index score more than or equal to 3
  • c Post void residual urine volume less than 100ml
  • d Maximum urine flow rate less than 15ml/sec

排除标准

  • 1 Suspected or diagnosed prostate cancer
  • 2 Acute urinary tract infections
  • 3 Neurogenic Bladder
  • 4 Use of silodosin or tadalafil within 12 weeks prior to treatment
  • 5 Use of anti-androgen or 5-α reductase inhibitor within 24 weeks prior to
  • 6 Severe cardiovascular , hepatic and/or renal disorders
  • 7 Cataract surgery planned during study period
  • 8 Acute bacterial prostatitis
  • 9 Postural hypotension
  • 10 Previous prostate surgeries
  • 11 Prior history of myocardial infarction or cerebrovascular accidents

研究者

发起方
Dr Mapranathukaran Devassy Robin

相似试验